Results 1 to 10 of about 5,445 (182)

The characteristics and outcomes in patients with acute heart failure who used tolvaptan: from KCHF registry

ESC Heart Failure, 2023
Aims The use of tolvaptan is increasing in clinical practice in Japan. However, the characteristics of patients who used tolvaptan and the timing of its use in patients with acute heart failure (AHF) are not fully elucidated.
Ryusuke Nishikawa, Takao Kato, Takeshi Morimoto, Hidenori Yaku, Yasutaka Inuzuka, Yodo Tamaki, Erika Yamamoto, Neiko Ozasa, Tomohisa Tada, Hiroki Sakamoto, Yuta Seko, Masayuki Shiba, Yusuke Yoshikawa, Yugo Yamashita, Takeshi Kitai, Ryoji Taniguchi, Moritake Iguchi, Kazuya Nagao, Takafumi Kawai, Akihiro Komasa, Yuichi Kawase, Takashi Morinaga, Mamoru Toyofuku, Yutaka Furukawa, Kenji Ando, Kazushige Kadota, Yukihito Sato, Koichiro Kuwahara, Takeshi Kimura, for the KCHF Study Investigators   +29 more
doaj   +2 more sources

Intravenous Tolvaptan Sodium Phosphate Can Fail to Improve Fluid Overload Due to Heart Failure in Patients With Chronic Kidney Disease: A Case Report. [PDF]

Pharmacol Res Perspect
ABSTRACT Tolvaptan is widely used as an adjunct oral diuretic to loop and thiazide diuretics for the management of fluid overload in patients with congestive heart failure. Recently, tolvaptan sodium phosphate (TSP), a water‐soluble prodrug of tolvaptan, was developed for intravenous administration and has demonstrated efficacy and safety in clinical ...
Uno T, Nakakura I, Ikeda A, Hosoda A, Mukai Y, Yamanishi K, Ohara N, Imanishi K, Une Y, Yokoyama S, Hosomi K.   +10 more
europepmc   +2 more sources

Real-World Effectiveness of Tolvaptan for Hyponatremia in Cirrhosis Across Global Regions: A Target Trial Emulation. [PDF]

JGH Open
ABSTRACT Background Tolvaptan promotes electrolyte‐free water excretion and is widely used in Asia for ascites, but in Western countries its use is limited to hyponatremia because of hepatotoxicity concerns. Methods We performed a retrospective cohort study using the TriNetX Research Network, emulating a target trial of cirrhotic patients with ...
Okushin K, Tateishi R, Fujishiro M, Tsutsumi T, Koike K, Tanaka T.   +5 more
europepmc   +2 more sources

Caring for Australians and New ZealandeRs with kidney Impairment guideline commentary on kidney disease: improving global outcomes 2025 guidelines for diagnosis and management of autosomal polycystic kidney disease. [PDF]

Intern Med J
Abstract Autosomal polycystic kidney disease (ADPKD) is the most common form of inherited kidney disease. The international guideline developer, Kidney Disease: Improving Global Outcomes (KDIGO), published a 2025 clinical practice guideline reflecting advances in genetic testing and the first disease‐modifying agent, tolvaptan.
Abdy ME, St Pierre K, Major E, Alexander SI, Cashmore B, Coolican H, Cullen V, Dawson J, Lambert K, Lee VW, Mallawaarachi A, Rangan G, Savige J, Varughese S, Tunnicliffe DJ, Mallett AJ, CARI Guidelines Steering Committee.   +16 more
europepmc   +2 more sources

Renoprotective Effect of Tolvaptan in Patients with New-Onset Acute Heart Failure

ESC Heart Failure, 2020
Aims Although tolvaptan has been reported to prevent worsening renal function (WRF) in patients with advanced acute heart failure (AHF), evidence regarding the effect of tolvaptan on renal function in patients with new‐onset AHF is not available.
Koichiro Matsumura, Kenichi Fujii, Munemitsu Otagaki   +2 more
exaly   +2 more sources

Trajectories of Kidney Function in Autosomal Dominant Polycystic Kidney Disease Patients Treated with Tolvaptan [PDF]

Medicina
Background and Objectives: Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic kidney disease, and the only approved pharmacological therapy shown to slow disease progression is tolvaptan.
Zofia Jankowska, Mariusz Niemczyk
doaj   +2 more sources

Unexplained Hyponatremia Revealing Vitamin D Deficiency: A Clinical Case Report. [PDF]

Clin Case Rep
ABSTRACT “SIAD” (syndrome of inappropriate antidiuresis) is frequently encountered in clinical practice, often necessitating the exclusion of various differential diagnoses and involving expensive treatments. In cases of SIAD concomitant with vitamin D deficiency, treatment with vitamin D supplementation may not only correct hyponatremia but also ...
Yavuz Ileri S.
europepmc   +2 more sources

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use

PLoS ONE, 2022
Polycystic liver disease (PLD) is a common extrarenal complication of autosomal dominant polycystic kidney disease (ADPKD), which causes compression-related syndrome and ultimately leads to liver dysfunction.
Hiroki Mizuno, Akinari Sekine, Tatsuya Suwabe, Daisuke Ikuma, Masayuki Yamanouchi, Eiko Hasegawa, Naoki Sawa, Yoshifumi Ubara, Junichi Hoshino   +8 more
doaj   +2 more sources

The effect of tolvaptan on renal progression and systemic inflammation in ADPKD [PDF]

Scientific Reports
Inflammation plays a crucial role in the progression of autosomal dominant polycystic kidney disease (ADPKD). While tolvaptan is primarily known for its vasopressin V2 receptor antagonism, its potential anti-inflammatory effects remain under ...
Ahmet Ziya Şahin, Orhan Özdemir
doaj   +2 more sources

In vitro and in vivo pharmacological profile of OPC-61815, a water-soluble phosphate ester pro-drug of tolvaptan

Journal of Pharmacological Sciences, 2022
Tolvaptan is an orally active vasopressin V2 receptor antagonist and used for the treatment of volume overload in some disease as an aquaretic. Tolvaptan sodium phosphate (OPC-61815) is a pro-drug of tolvaptan that was designed to improve water ...
Hiroyuki Fujiki, Masayuki Matsunaga, Masayuki Furukawa, Tatsuya Yamashita, Shigeki Nakamura, Toshiki Miyazaki, Hiroshi Mizuguchi, Yasuhiro Menjo, Takakuni Matsuda, Yoshihisa Yamada   +9 more
doaj   +1 more source